Sukari, Ammar

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 185